The UK’s Technology Strategy Board has awarded Domainex a £250,000 grant to develop of a new drug to treat several common cancers.

The drug will act by inhibiting two protein kinases, TBK1 and IKKe, which will suppress certain cancer cell lines from growing.

The aim of the project is to identify a drug candidate that is effective in disease models and would be orally well-absorbed by humans.

Domainex research director Trevor Perrior said that the novel mode of action will allow the treatment of patients with drug-resistant, triple-negative tumours.

The marketing of the new drug will be done in partnership with a large pharmaceutical company that has the ability to conduct drug trials, Domainex said.